PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

This study is testing a combination of two drugs — trametinib (a targeted cancer drug) and hydroxychloroquine (a drug also used for malaria and autoimmune conditions) — in patients with advanced pancreatic cancer that has spread and has not responded to prior treatments. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with advanced or metastatic pancreatic cancer (confirmed by pathology) - You have received at least one prior round of chemotherapy for metastatic disease - Your cancer is measurable on imaging scans - Your heart, kidneys, and liver are functioning adequately - Your overall health is good enough for treatment (ECOG performance status ≤1) **You may NOT be eligible if...** - Your cancer cannot be biopsied - You cannot have surgery to remove the cancer - Your organ function (liver, kidneys, blood counts) is significantly impaired - You are pregnant or breastfeeding, or unwilling to use effective contraception Talk to your doctor to see if this trial is right for you.